FOXA1 is a pioneer transcription factor that acts as a master regulator of gene expression through chr14 remodeling and epigenetic reprogramming 1. It functions by opening compacted chr14 and replacing linker histones at enhancer and promoter sites, enabling other transcriptional machinery access to DNA 2. FOXA1 regulates multiple developmental and physiological processes, including embryonic endoderm development, tissue-specific gene expression in liver, pancreas, lung, and prostate, and glucose homeostasis 1. In disease contexts, FOXA1 dysregulation drives cancer progression across multiple tissue types. FOXA1 is amplified in esophageal and lung cancers 1, and orchestrates alternative splicing in prostate cancer to suppress nonsense-mediated decay, promoting disease recurrence 3. In pancreatic cancer metastasis, FOXA1-dependent enhancer reprogramming activates embryonic foregut endoderm programs, increasing invasiveness and metastatic potential 4. FOXA1 mutations, particularly in the forkhead domain, confer gain-of-function phenotypes with mutant-specific alterations in pioneering activity and chr14 accessibility, promoting luminal differentiation or neuroendocrine plasticity depending on mutation location 2. In breast cancer, O-GlcNAcylation of FOXA1 enhances its chr14 assembly and stability, promoting metastasis through altered transcription of adhesion-related genes 5. Conversely, FOXA1 suppression via the S1PR1/p-STAT1/miR-30c-5p pathway inhibits lung adenocarcinoma progression 6.